Determining the Safety of L-serine in ALS

Study Purpose:

Disease:

Amyotrophic Lateral Sclerosis (ALS)

Study Type:

Interventional Trial

Study Category:

Drug Trial

Study Status:

Closed

Phase:

Phase I

Study Chair(s)/Principal Investigator(s):

Todd D Levine, MD

Clinicaltrials.gov ID (11 digit #):

NCT01835782

Neals Affiliated?

No

Coordinating Center Contact Information

Phoenix Neurological Associates
Nicole Hank, MHSM / .(JavaScript must be enabled to view this email address) / 602-258-2432
.(JavaScript must be enabled to view this email address) United States

Full Study Summary:

The purpose of this study is to determine the safety of L-Serine in subjects with Amyotrophic Lateral Sclerosis (ALS) at varied doses.

Study Sponsor:

Phoenix Neurological Associates

Participant Duration:

1-6 months

Estimated Enrollment:

20

Estimated Study Start Date:

10/31/2013

Estimated Study Completion Date:

11/02/2016

Posting Last Modified Date:

11/02/2016

Date Study Added to alsconsortium.org:

09/10/2014